aspartame

• Ames/Salmonella/microsome mutagenicity test, TA98 and TA100 strains

  no effect

  ASP was not mutagenic for Salmonella typhimurium TA98 and TA100 strains in the absence and presence of S9 mix.

  PMID:15478947 · one of two readings recorded this

• Ames/Salmonella/microsome mutagenicity test

  no effect

  ASP was not mutagenic for Salmonella typhimurium TA98 and TA100 strains in the absence and presence of S9 mix.

  PMID:15478947 · one of two readings recorded this

• chromosome aberration (CA) test, human lymphocytes

  increases

  ASP induced CAs at all concentrations (500, 1000 and 2000 microg/ml) and treatment periods (24 and 48 h) dose-dependently, while it did not induce SCEs.

  PMID:15478947 · one of two readings recorded this

• chromosome aberration (CA) test in human lymphocytes

  increases

  ASP induced CAs at all concentrations (500, 1000 and 2000 microg/ml) and treatment periods (24 and 48 h) dose-dependently, while it did not induce SCEs.

  PMID:15478947 · one of two readings recorded this

• chromosome aberration frequency in human lymphocytes, chromosome aberration (CA) test

  increases

  Not recorded as a finding: this platform holds no node for the endpoint

  ASP induced CAs at all concentrations (500, 1000 and 2000 microg/ml) and treatment periods (24 and 48 h) dose-dependently, while it did not induce SCEs.

  PMID:15478947 · one of two readings recorded this

• genotoxicity of aspartame in human lymphocytes (chromosome aberration, sister chromatid exchange, micronucleus, mitotic and replication indices) and mutagenicity in the Ames Salmonella/microsome test

  increases

  Not recorded as a finding: this platform holds no node for the endpoint

  ASP induced CAs at all concentrations (500, 1000 and 2000 microg/ml) and treatment periods (24 and 48 h) dose-dependently, while it did not induce SCEs.

  PMID:15478947 · one of two readings recorded this

• micronucleus test, human lymphocytes

  increases

  In addition, ASP induced micronuclei at the highest concentrations only.

  PMID:15478947 · one of two readings recorded this

• micronucleus test in human lymphocytes

  increases

  In addition, ASP induced micronuclei at the highest concentrations only.

  PMID:15478947 · one of two readings recorded this

• mitotic index (MI), human lymphocytes

  decreases

  However, ASP decreased the mitotic index (MI) at all concentrations and treatment periods dose-dependently.

  PMID:15478947 · one of two readings recorded this

• mitotic index (MI) in human lymphocytes

  decreases

  However, ASP decreased the mitotic index (MI) at all concentrations and treatment periods dose-dependently.

  PMID:15478947 · one of two readings recorded this

• replication index (RI), human lymphocytes

  decreases

  On the other hand, ASP decreased the replication index (RI) only at the highest concentration for 48 h treatment period.

  PMID:15478947 · one of two readings recorded this

• replication index (RI) in human lymphocytes

  decreases

  ASP decreased the replication index (RI) only at the highest concentration for 48 h treatment period.

  PMID:15478947 · one of two readings recorded this

• sister chromatid exchange (SCE) test, human lymphocytes

  no effect

  ASP induced CAs at all concentrations (500, 1000 and 2000 microg/ml) and treatment periods (24 and 48 h) dose-dependently, while it did not induce SCEs.

  PMID:15478947 · one of two readings recorded this

• sister chromatid exchange (SCE) test in human lymphocytes

  no effect

  ASP induced CAs at all concentrations (500, 1000 and 2000 microg/ml) and treatment periods (24 and 48 h) dose-dependently, while it did not induce SCEs.

  PMID:15478947 · one of two readings recorded this

• incidence of malignant-tumor-bearing animals, positive trend

  increases, p = 0.01

  an increased incidence of malignant-tumor-bearing animals with a positive significant trend in males (p < or = 0.05) and in females (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• incidence of malignant-tumor-bearing animals, positive trend

  increases, p = 0.05

  an increased incidence of malignant-tumor-bearing animals with a positive significant trend in males (p < or = 0.05) and in females (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• incidence of malignant-tumor-bearing animals

  increases, p = 0.01

  in particular those females treated at 50,000 ppm (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• lymphomas and leukemias incidence, positive trend

  increases, p = 0.01

  an increase in lymphomas and leukemias with a positive significant trend in both males (p < or = 0.05) and females (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• lymphomas and leukemias incidence, positive trend

  increases, p = 0.05

  an increase in lymphomas and leukemias with a positive significant trend in both males (p < or = 0.05) and females (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• lymphomas and leukemias incidence

  increases, p = 0.05

  in particular in females treated at doses of 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.05), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• lymphomas and leukemias incidence

  increases, p = 0.01

  in particular in females treated at doses of 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.05), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• lymphomas and leukemias incidence

  increases, p = 0.05

  in particular in females treated at doses of 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.05), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• lymphomas and leukemias incidence

  increases, p = 0.01

  in particular in females treated at doses of 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.05), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• lymphomas and leukemias incidence

  increases, p = 0.01

  in particular in females treated at doses of 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.05), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.01)

  PMID:16507461 · one of two readings recorded this

• malignant schwannomas of peripheral nerves, positive trend

  increases, p = 0.05

  an increased incidence of malignant schwannomas of peripheral nerves with a positive trend (p < or = 0.05) in males

  PMID:16507461 · one of two readings recorded this

• transitional cell carcinomas of renal pelvis and ureter and precursors (dysplasias), positive trend

  increases, p = 0.01

  with a positive significant trend (p < or = 0.01), of transitional cell carcinomas of the renal pelvis and ureter

  PMID:16507461 · one of two readings recorded this

• transitional cell carcinomas of renal pelvis and ureter and precursors (dysplasias)

  increases, p = 0.01

  in females treated at 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.01), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.05)

  PMID:16507461 · one of two readings recorded this

• transitional cell carcinomas of renal pelvis and ureter and precursors (dysplasias)

  increases, p = 0.01

  in females treated at 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.01), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.05)

  PMID:16507461 · one of two readings recorded this

• transitional cell carcinomas of renal pelvis and ureter and precursors (dysplasias)

  increases, p = 0.05

  in females treated at 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.01), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.05)

  PMID:16507461 · one of two readings recorded this

• transitional cell carcinomas of renal pelvis and ureter and precursors (dysplasias)

  increases, p = 0.05

  in females treated at 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.01), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.05)

  PMID:16507461 · one of two readings recorded this

• transitional cell carcinomas of renal pelvis and ureter and precursors (dysplasias)

  increases, p = 0.01

  in females treated at 100,000 (p < or = 0.01), 50,000 (p < or = 0.01), 10,000 (p < or = 0.01), 2,000 (p < or = 0.05), or 400 ppm (p < or = 0.05)

  PMID:16507461 · one of two readings recorded this

• feed and water consumption

  no effect

  We observed no relevant differences in feed consumption between treated and untreated groups, in either males or females

  PMID:17805418 · one of two readings recorded this

• historical control incidence of lymphomas/leukemias, female rats

  n = 2274

  the overall incidence of lymphomas/leukemias was 20.6% (range, 8.0–30.9%) among 2,265 male rats and 13.3% (range, 4.0–25.0%) among 2,274 female rats

  PMID:17805418 · one of two readings recorded this

• historical control incidence of lymphomas/leukemias, male rats

  n = 2265

  the overall incidence of lymphomas/leukemias was 20.6% (range, 8.0–30.9%) among 2,265 male rats and 13.3% (range, 4.0–25.0%) among 2,274 female rats

  PMID:17805418 · one of two readings recorded this

• historical control incidence of mammary cancers, female rats

  The overall incidence of mammary cancers in the same group of female rats was 9.2% (range, 4.0–14.2%)

  PMID:17805418 · one of two readings recorded this

• incidence of lymphomas/leukemias, histopathology at necropsy

  increases, significant at 2,000 ppm in males and females; dose-related in females

  Not recorded as a finding: no outcome node for lymphoma/leukaemia incidence

  When compared with the untreated control group, the increased incidence of lymphomas/ leukemias in treated males and females was significant at 2,000 ppm APM (p ≤ 0.05 and p ≤ 0.01, respectively).

  PMID:17805418 · one of two readings recorded this

• incidence of lymphomas/leukemias

  increases, p = 0.01

  the increased incidence of lymphomas/ leukemias in treated males and females was significant at 2,000 ppm APM (p ≤ 0.05 and p ≤ 0.01, respectively)

  PMID:17805418 · one of two readings recorded this

• incidence of lymphomas/leukemias

  increases, p = 0.05

  the increased incidence of lymphomas/ leukemias in treated males and females was significant at 2,000 ppm APM (p ≤ 0.05 and p ≤ 0.01, respectively)

  PMID:17805418 · one of two readings recorded this

• incidence of lymphomas/leukemias

  increases, p = 0.01

  The data show that APM causes a significant, dose-related increased incidence in females (p ≤ 0.01)

  PMID:17805418 · one of two readings recorded this

• incidence of malignant tumor-bearing animals, lymphomas/leukemias and mammary carcinomas by histopathology at natural death, in Sprague-Dawley rats given aspartame in feed at 2,000 or 400 ppm from fetal day 12 for life, with Cox regression for dose-response

  increases, malignant tumor incidence significantly increased in males at 2,000 ppm aspartame; the numeric rise in females was not significant

  Not recorded as a finding: every result is a subgroup, with no whole-population estimate

  The incidence of malignant tumors was significantly increased in males treated with 2,000 ppm APM (p ≤ 0.01) compared with controls (Table 1).

  PMID:17805418 · one of two readings recorded this

• incidence of malignant tumor-bearing animals

  increases

  Albeit not significant, a numeric increase of the incidence of animals bearing malignant tumors was also observed among females exposed to 2,000 ppm APM compared with controls (Table 2)

  PMID:17805418 · one of two readings recorded this

• incidence of malignant tumor-bearing animals

  increases, p = 0.01

  The incidence of malignant tumors was significantly increased in males treated with 2,000 ppm APM (p ≤ 0.01) compared with controls (Table 1)

  PMID:17805418 · one of two readings recorded this

• incidence of malignant tumor-bearing animals

  increases, p = 0.01

  The incidence of malignant tumor–bearing animals occurred with a significant, dose-related increase in males (p ≤ 0.01)

  PMID:17805418 · one of two readings recorded this

• incidence of mammary gland carcinomas in females, histopathology at necropsy

  increases, females at 2,000 ppm APM significantly higher than controls

  Not recorded as a finding: the sentences that carry the finding do not name the compound as subject (agentless), and breast-cancer-incidence node is registry or pathology diagnosis in people

  The incidence of lesions in females exposed to 2,000 ppm APM was significantly higher (p ≤ 0.05) compared with the controls.

  PMID:17805418 · one of two readings recorded this

• incidence of mammary gland carcinomas

  increases, p = 0.05

  The incidence of lesions in females exposed to 2,000 ppm APM was significantly higher (p ≤ 0.05) compared with the controls

  PMID:17805418 · one of two readings recorded this

• incidence of mammary gland carcinomas

  increases, p = 0.05

  A dose-related increase in the incidence of carcinomas was observed in females (p ≤ 0.05)

  PMID:17805418 · one of two readings recorded this

• mammary carcinomas in males

  unclear

  Two carcinomas were also observed among males treated with 2,000 ppm APM

  PMID:17805418 · one of two readings recorded this

• mean body weight, weekly then fortnightly

  no effect, no difference in mean body weight between treated groups and controls

  Not recorded as a finding: agentless sentence naming 'the treated groups' with no compound; absence is stated one-way only for survival

  No difference in mean body weight was observed in the treated groups compared with the controls.

  PMID:17805418 · one of two readings recorded this

• mean body weight

  no effect

  No difference in mean body weight was observed in the treated groups compared with the controls

  PMID:17805418 · one of two readings recorded this

• survival

  decreases

  We observed a slight decrease, seemingly dose related, in survival in the treated groups compared with the control group in both males and females

  PMID:17805418 · one of two readings recorded this

• HDL cholesterol

  decreases

  HDL-C (mg/dL) | 77.13 | ± | 3.55 | 63.25** | ± | 3.04 | 54.47§§ | ± | 2.73 | 41.45**§§ | ± | 2.23

  PMID:22509243 · one of two readings recorded this

• HOMA-IR

  no effect

  HOMA-IR | 2.36 | ± | 0.35 | 3.19 | ± | 0.24 | 1.35§ | ± | 0.11 | 1.29§§ | ± | 0.1

  PMID:22509243 · one of two readings recorded this

• LDL cholesterol

  increases

  LDL (mg/dL) | 23.54 | ± | 3.10 | 36.34* | ± | 3.42 | 42.80 | ± | 2.63 | 60.89**§§ | ± | 2.41

  PMID:22509243 · one of two readings recorded this

• annulus crossing index, probe test

  decreases, p = 0.01

  male aspartame-fed mice crossed the former location of the platform significantly less frequently than controls (<0.01), and had a lower Annulus Crossing Index (<0.01)

  PMID:22509243 · one of two readings recorded this

• aspartame ingestion

  Averaged aspartame ingestion in the drinking water was 55.14±4.74 mg/Kg body weight

  PMID:22509243 · one of two readings recorded this

• body length and visceral fat deposition

  increases, p = 0.01

  Body length and visceral fat deposition were both increased in aspartame-fed mice of both sexes (Table 1, P<0.01)

  PMID:22509243 · one of two readings recorded this

• body length

  increases

  Length (cm) | 9.65 | ± | 0.08 | 10.04** | ± | 0.08 | 9.21 | ± | 0.07 | 9.52**§§ | ± | 0.06

  PMID:22509243 · one of two readings recorded this

• body weight at 17 weeks

  no effect

  Body Weight (17 weeks) | 24.02 | ± | 0.48 | 24.96 | ± | 0.4 | 18.91§§ | ± | 0.21 | 19.42§§ | ± | 0.27

  PMID:22509243 · one of two readings recorded this

• body weight at 6 weeks

  no effect

  Body Weight (6 weeks) | 17.6 | ± | 0.13 | 17.22 | ± | 0.35 | 14.31§§ | ± | 0.17 | 14.34§§ | ± | 0.22

  PMID:22509243 · one of two readings recorded this

• correlation of body weight at 6 weeks with body weight at 17 weeks

  p = 0.001

  body weight at six weeks of age strongly correlated with weight at 17 weeks (Table 2, r = 0.888, P<0.001)

  PMID:22509243 · one of two readings recorded this

• correlation of visceral fat with probe-test annulus crossing index

  decreases

  Probe Test | −0.213 | −0.027 | −0.359* | −0.004 | −0.074 | −0.052 | 0.048 | 0.317* | −0.303*

  PMID:22509243 · one of two readings recorded this

• correlation of visceral fat with probe-test floating time

  increases

  Probe Test | 0.258 | 0.188 | 0.457** | −0.077 | 0.433** | 0.177 | 0.202 | 0.012 | 0.074

  PMID:22509243 · one of two readings recorded this

• correlation of visceral fat with probe-test latency

  increases

  Probe Test | 0.211 | 0.076 | 0.431** | 0.017 | 0.207 | 0.150 | −0.116 | −0.257 | 0.281*

  PMID:22509243 · one of two readings recorded this

• correlation of visceral fat with probe-test platform crosses

  decreases

  Probe Test | −0.265 | −0.120 | −0.401** | 0.023 | −0.157 | −0.080 | −0.005 | 0.223 | −0.221

  PMID:22509243 · one of two readings recorded this

• correlation of visceral fat with probe-test thigmotaxis

  increases

  Probe Test | −0.010 | 0.211 | 0.356* | 0.001 | 0.259 | 0.133 | 0.061 | 0.123 | −0.097

  PMID:22509243 · one of two readings recorded this

• escape latency, acquisition

  increases, p = 0.05

  latencies of male aspartame-treated mice were higher than control latencies on the last 2 days of the 4-day trial (<0.05)

  PMID:22509243 · one of two readings recorded this

• fasting blood glucose, both sexes

  increases, p = 0.01

  aspartame-fed mice had elevated fasting blood glucose levels compared to non-consumers of both sexes, although females had lower levels than males (Table 1, P<0.01)

  PMID:22509243 · one of two readings recorded this

• fasting glucose

  increases

  Fasting Glucose (mM) | 3.1 | ± | 0.18 | 4.61** | ± | 0.43 | 2.93 | ± | 0.13 | 3.65**§ | ± | 0.17

  PMID:22509243 · one of two readings recorded this

• fasting insulin

  decreases

  Fasting Insulin (uIU/ml) | 17.32 | ± | 2.54 | 16.67 | ± | 1.86 | 10.37§ | ± | 0.8 | 8*§§ | ± | 0.58

  PMID:22509243 · one of two readings recorded this

• floating time, acquisition

  increases, p = 0.001

  with male aspartame-fed mice exhibiting increased floating behavior on days 2,3 and 4 compared to controls (<0.001)

  PMID:22509243 · one of two readings recorded this

• GLM p-value: annulus crossing index, probe test

  no effect, p = 0.199

  Annulus Crossing Index | 0.263 | 0.536 | 0.290 | 0.619 | 0.199

  PMID:22509243 · one of two readings recorded this

• GLM p-value: annulus crossing index, probe test

  decreases, p = 0.001

  Annulus Crossing Index | 0.781 | 0.569 | <.01 | 0.553 | <.001

  PMID:22509243 · one of two readings recorded this

• GLM p-value: floating time, probe test

  no effect, p = 0.175

  Floating (% time) | 0.191 | 0.347 | 0.640 | <.01 | 0.175

  PMID:22509243 · one of two readings recorded this

• GLM p-value: floating time, probe test

  increases, p = 0.05

  Floating time (%) | 0.348 | <.01 | <.001 | <.001 | <.05

  PMID:22509243 · one of two readings recorded this

• GLM p-value: latency, probe test

  no effect, p = 0.474

  Latency | 0.817 | 0.359 | 0.644 | 0.090 | 0.474

  PMID:22509243 · one of two readings recorded this

• GLM p-value: latency, probe test

  unclear, p = 0.001

  Latency | 0.862 | 0.061 | <.001 | <.01 | <.001

  PMID:22509243 · one of two readings recorded this

• GLM p-value: mean distance to goal, probe test

  increases, p = 0.05

  Mean distance to goal (m) | 0.626 | 0.822 | 0.291 | <.05 | <.05

  PMID:22509243 · one of two readings recorded this

• GLM p-value: mean distance to goal, probe test

  increases, p = 0.05

  Mean distance to goal (m) | <.05 | <.05 | <.001 | <.001 | <.05

  PMID:22509243 · one of two readings recorded this

• GLM p-value: platform crosses, probe test

  no effect, p = 0.277

  Platform Crosses | 0.225 | 0.339 | 0.650 | 0.153 | 0.277

  PMID:22509243 · one of two readings recorded this

• GLM p-value: platform crosses, probe test

  decreases, p = 0.001

  Platform Crosses | 0.715 | 0.547 | <.001 | 0.800 | <.001

  PMID:22509243 · one of two readings recorded this

• GLM p-value: thigmotaxis time, probe test

  no effect, p = 0.818

  Thigmotaxis (% time) | 0.623 | 0.957 | 0.452 | <.05 | 0.818

  PMID:22509243 · one of two readings recorded this

• GLM p-value: thigmotaxis time, probe test

  no effect, p = 0.236

  Thigmotaxis time (%) | <.01 | <.01 | <.0001 | <.0001 | 0.236

  PMID:22509243 · one of two readings recorded this

• GLM p-value: time in non-target quadrants, probe test

  increases, p = 0.05

  Time in non-target quadrants (%) | 0.321 | 0.895 | 0.602 | 0.175 | <.05

  PMID:22509243 · one of two readings recorded this

• GLM p-value: time in non-target quadrants, probe test

  no effect, p = 0.111

  Time in non-target quadrants (%) | <.01 | 0.076 | <.05 | 0.112 | 0.111

  PMID:22509243 · one of two readings recorded this

• GLM p-value: time in target quadrant, probe test

  decreases, p = 0.05

  Time in target quadrant (%) | 0.321 | 0.897 | 0.605 | 0.176 | <.05

  PMID:22509243 · one of two readings recorded this

• GLM p-value: time in target quadrant, probe test

  no effect, p = 0.112

  Time in target quadrant (%) | <.01 | 0.076 | <.05 | 0.112 | 0.112

  PMID:22509243 · one of two readings recorded this

• glucose after insulin challenge, random-fed ITT

  increases, p = 0.001

  glucose levels in male aspartame-fed mice were 120.2% higher than control mice following insulin challenge (= 0.001)

  PMID:22509243 · one of two readings recorded this

• ITT AUCtotal

  no effect, p = 0.19

  AUCtotal (mM x min) | 4819.93 | ± | 190.36 | 5194.63 | ± | 208.04 | 0.19

  PMID:22509243 · one of two readings recorded this

• ITT AUCtotal

  increases, p = 0.001

  AUCtotal (mM x min) | 4829.58 | ± | 131.96 | 5829.79 | ± | 197.07 | <.001

  PMID:22509243 · one of two readings recorded this

• ITT glucose half-life T½

  no effect, p = 0.31

  T½ (min) | 34.19 | ± | 4.4 | 23.28 | ± | 9.59 | 0.31

  PMID:22509243 · one of two readings recorded this

• ITT glucose half-life T½

  no effect, p = 0.59

  T½ (min) | 39.69 | ± | 14.05 | 51.61 | ± | 16.63 | 0.59

  PMID:22509243 · one of two readings recorded this

• ITT Kglucose

  no effect, p = 0.31

  Kglucose (%/min) | 2.71 | ± | 0.37 | 2.24 | ± | 0.26 | 0.31

  PMID:22509243 · one of two readings recorded this

• ITT Kglucose

  no effect, p = 0.15

  Kglucose (%/min) | 2.92 | ± | 0.28 | 2.32 | ± | 0.29 | 0.15

  PMID:22509243 · one of two readings recorded this

• liver weight

  increases

  Liver Weight (g) | 0.89 | ± | 0.02 | 1.03* | ± | 0.06 | 0.76 | ± | 0.03 | 0.71§§ | ± | 0.02

  PMID:22509243 · one of two readings recorded this

• mean distance to goal, acquisition

  increases, p = 0.05

  aspartame-fed mice were farther from their goal than controls on all four days of acquisition training, suggestive of impaired learning (<0.05)

  PMID:22509243 · one of two readings recorded this

• percent weight gain between 6 and 17 weeks of age

  increases, weight gain significantly higher in male aspartame group; female weight gain unaffected, p = 0.024

  Not recorded as a finding: Reported as significant in males only (P = 0.024) with females unaffected, so the whole-population contrast is not a single estimate; gain from baseline is not total body mass

  Weight gain was significantly higher in the male aspartame diet group compared to controls (Table 1, P = 0.024), but female weight gain was unaffected by diet.

  PMID:22509243 · one of two readings recorded this

• platform crossings, probe test

  decreases, p = 0.01

  male aspartame-fed mice crossed the former location of the platform significantly less frequently than controls (<0.01), and had a lower Annulus Crossing Index (<0.01)

  PMID:22509243 · one of two readings recorded this

• relative weight of liver

  modulates

  RW of Liver (g/20g BW) | 0.75 | ± | 0.02 | 0.82 | ± | 0.04 | 0.81 | ± | 0.03 | 0.736* | ± | 0.02

  PMID:22509243 · one of two readings recorded this

• relative weight of visceral fat

  increases

  RW of Visceral Fat (g/20g BW) | 0.08 | ± | 0.01 | 0.192** | ± | 0.02 | 0.09 | ± | 0.01 | 0.13**§§ | ± | 0.01

  PMID:22509243 · one of two readings recorded this

• serum triglycerides

  modulates

  TG (mg/dL) | 104.17 | ± | 7.42 | 107.41 | ± | 5.88 | 123.25 | ± | 6.67 | 98.24* | ± | 6.32

  PMID:22509243 · one of two readings recorded this

• spatial and directional search strategies, acquisition

  decreases, p = 0.05

  compared to control, aspartame-fed mice exhibited significantly less time acquiring spatial and directional strategies to find the hidden platform during the acquisition training (<0.05)

  PMID:22509243 · one of two readings recorded this

• spatial learning and reference memory in the Morris water maze (probe-test time swimming at the former platform location, acquisition latency, thigmotaxis, floating); also fasting blood glucose by Ascensia Contour glucometer and percent weight gain

  decreases, aspartame-fed mice of both genders spent significantly less time swimming towards the former platform position than control, P < 0.05

  Not recorded as a finding: this platform holds no node for the endpoint

  Once the platform had been removed, aspartame-fed mice of both genders spent significantly less time swimming towards the former position of the hidden platform compared to control, (<0.05).

  PMID:22509243 · one of two readings recorded this

• thigmotaxis, acquisition

  increases, p = 0.01

  Thigmotaxis, defined as percentage of time spent swimming within 16cm of the pool wall, was greatly increased in aspartame-treated males throughout the whole experiment (<0.01)

  PMID:22509243 · one of two readings recorded this

• time in target quadrant, acquisition

  decreases, p = 0.05

  aspartame-fed males spent significantly less time searching for the platform in the target quadrant (<0.05)

  PMID:22509243 · one of two readings recorded this

• time swimming toward former platform position, probe test

  decreases, p = 0.05

  aspartame-fed mice of both genders spent significantly less time swimming towards the former position of the hidden platform compared to control, (<0.05)

  PMID:22509243 · one of two readings recorded this

• total cholesterol

  no effect

  T-CHOL (mg/dL) | 121.5 | ± | 1.08 | 121.08 | ± | 1.4 | 121.92 | ± | 0.91 | 122 | ± | 0.46

  PMID:22509243 · one of two readings recorded this

• visceral fat

  increases

  Visceral Fat (g) | 0.09 | ± | 0.02 | 0.24** | ± | 0.02 | 0.08 | ± | 0.01 | 0.13**§§ | ± | 0.01

  PMID:22509243 · one of two readings recorded this

• % weight gain (6-17 weeks)

  increases

  % Weight Gain | 36.42 | ± | 2.44 | 45.31* | ± | 2.71 | 32.3 | ± | 1.45 | 35.63§§ | ± | 1.5

  PMID:22509243 · one of two readings recorded this

• weight gain, males

  increases, p = 0.024

  Weight gain was significantly higher in the male aspartame diet group compared to controls (Table 1, P = 0.024)

  PMID:22509243 · one of two readings recorded this

• Angiogenesis, CAM assay

  increases

  In CAM assay, aspartame increased angiogenesis in a concentration-dependent manner

  PMID:24925367 · one of two readings recorded this

• Antiangiogenic effect, tube formation assay

  no effect

  there was no antiangiogenic effect of aspartame on tube formation assay in vitro

  PMID:24925367 · one of two readings recorded this

• HUVEC proliferation, XTT assay

  no effect

  There was a slight proliferative effect of aspartame on human umbilical vein endothelial cells on XTT assay in vitro, but it was not statistically significant

  PMID:24925367 · one of two readings recorded this

• Skin wound healing, rat model

  increases, p = 0.05

  in vivo rat model of skin wound-healing study showed that aspartame group had better healing than control group, and this was statistically significant at p < 0.05

  PMID:24925367 · one of two readings recorded this

• Vessel proliferation, CAM assay

  increases, p = 0.001

  Compared with the control group, aspartame has significantly increased vessel proliferation (p < 0.001)

  PMID:24925367 · one of two readings recorded this

• vessel proliferation in the chick chorioallantoic membrane assay, skin wound healing in rats, XTT proliferation and tube formation in human umbilical vein endothelial cells

  increases

  Not recorded as a finding: this platform holds no node for the endpoint

  Compared with the control group, aspartame has significantly increased vessel proliferation (p < 0.001).

  PMID:24925367 · one of two readings recorded this

• lipid accumulation in differentiated 3T3-L1 adipocytes by Oil Red O staining; PPARgamma, FABP4, C/EBPalpha mRNA by qRT-PCR; PPARgamma, SREBP1, adipsin protein by Western blot

  decreases

  Not recorded as a finding: this platform holds no node for the endpoint

  Aspartame reduced lipid accumulation in differentiated adipocytes as evidenced by Oil Red O staining.

  PMID:24961835 · one of two readings recorded this

• Lipid accumulation in differentiated adipocytes

  decreases

  Aspartame reduced lipid accumulation in differentiated adipocytes as evidenced by Oil Red O staining

  PMID:24961835 · one of two readings recorded this

• p-PPARγ, PPARγ, SREBP1 and adipsin protein induction

  decreases

  Western blot analysis showed that the induction of p-PPARγ, PPARγ, SREBP1, and adipsin was markedly reduced in the aspartame-treated adipocytes

  PMID:24961835 · one of two readings recorded this

• PPARγ, FABP4 and C/EBPα mRNA expression

  decreases

  qRT-PCR analysis showed that the PPARγ, FABP4, and C/EBPα mRNA expression was significantly reduced in the aspartame-treated adipocytes

  PMID:24961835 · one of two readings recorded this

• catalase activity

  increases

  cerebral cortex (F = 27, df = 2), cerebellum(F = 34, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 25, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• catalase activity

  increases

  cerebral cortex (F = 27, df = 2), cerebellum(F = 34, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 25, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• catalase activity

  increases

  cerebral cortex (F = 27, df = 2), cerebellum(F = 34, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 25, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• catalase activity

  increases

  cerebral cortex (F = 27, df = 2), cerebellum(F = 34, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 25, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• catalase activity

  increases

  cerebral cortex (F = 27, df = 2), cerebellum(F = 34, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 25, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• catalase activity

  increases

  cerebral cortex (F = 27, df = 2), cerebellum(F = 34, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 25, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione peroxidase activity

  increases

  cerebral cortex (F = 153, df = 2), cerebellum (F = 151, df = 2), midbrain (F = 43, df = 2), pons-medulla (F = 152, df = 2), hippocampus (F = 150, df = 2) and hypothalamus (F = 237, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione peroxidase activity

  increases

  cerebral cortex (F = 153, df = 2), cerebellum (F = 151, df = 2), midbrain (F = 43, df = 2), pons-medulla (F = 152, df = 2), hippocampus (F = 150, df = 2) and hypothalamus (F = 237, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione peroxidase activity

  increases

  cerebral cortex (F = 153, df = 2), cerebellum (F = 151, df = 2), midbrain (F = 43, df = 2), pons-medulla (F = 152, df = 2), hippocampus (F = 150, df = 2) and hypothalamus (F = 237, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione peroxidase activity

  increases

  cerebral cortex (F = 153, df = 2), cerebellum (F = 151, df = 2), midbrain (F = 43, df = 2), pons-medulla (F = 152, df = 2), hippocampus (F = 150, df = 2) and hypothalamus (F = 237, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione peroxidase activity

  increases

  cerebral cortex (F = 153, df = 2), cerebellum (F = 151, df = 2), midbrain (F = 43, df = 2), pons-medulla (F = 152, df = 2), hippocampus (F = 150, df = 2) and hypothalamus (F = 237, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione peroxidase activity

  increases

  cerebral cortex (F = 153, df = 2), cerebellum (F = 151, df = 2), midbrain (F = 43, df = 2), pons-medulla (F = 152, df = 2), hippocampus (F = 150, df = 2) and hypothalamus (F = 237, df = 2)

  PMID:25009784 · one of two readings recorded this

• reduced glutathione

  decreases

  cerebral cortex (F = 62, df = 2), cerebellum (F = 39, df = 2), midbrain (F = 40, df = 2), pons-medulla (F = 38, df = 2), hippocampus (F = 33, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• reduced glutathione

  decreases

  cerebral cortex (F = 62, df = 2), cerebellum (F = 39, df = 2), midbrain (F = 40, df = 2), pons-medulla (F = 38, df = 2), hippocampus (F = 33, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• reduced glutathione

  decreases

  cerebral cortex (F = 62, df = 2), cerebellum (F = 39, df = 2), midbrain (F = 40, df = 2), pons-medulla (F = 38, df = 2), hippocampus (F = 33, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• reduced glutathione

  decreases

  cerebral cortex (F = 62, df = 2), cerebellum (F = 39, df = 2), midbrain (F = 40, df = 2), pons-medulla (F = 38, df = 2), hippocampus (F = 33, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• reduced glutathione

  decreases

  cerebral cortex (F = 62, df = 2), cerebellum (F = 39, df = 2), midbrain (F = 40, df = 2), pons-medulla (F = 38, df = 2), hippocampus (F = 33, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• reduced glutathione

  decreases

  cerebral cortex (F = 62, df = 2), cerebellum (F = 39, df = 2), midbrain (F = 40, df = 2), pons-medulla (F = 38, df = 2), hippocampus (F = 33, df = 2) and hypothalamus (F = 50, df = 2)

  PMID:25009784 · one of two readings recorded this

• activated caspase 3 mRNA expression

  increases

  cerebral cortex (F = 174.98, df = 2), cerebellum (F = 71.51, df = 2), hippocampus (F = 167.36, df = 2) and hypothalamus (F = 5.08, df = 2)

  PMID:25009784 · one of two readings recorded this

• activated caspase 3 mRNA expression

  increases

  cerebral cortex (F = 174.98, df = 2), cerebellum (F = 71.51, df = 2), hippocampus (F = 167.36, df = 2) and hypothalamus (F = 5.08, df = 2)

  PMID:25009784 · one of two readings recorded this

• activated caspase 3 mRNA expression

  increases

  cerebral cortex (F = 174.98, df = 2), cerebellum (F = 71.51, df = 2), hippocampus (F = 167.36, df = 2) and hypothalamus (F = 5.08, df = 2)

  PMID:25009784 · one of two readings recorded this

• activated caspase 3 mRNA expression

  increases

  cerebral cortex (F = 174.98, df = 2), cerebellum (F = 71.51, df = 2), hippocampus (F = 167.36, df = 2) and hypothalamus (F = 5.08, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bax mRNA expression

  increases

  cerebral cortex (F = 57.62, df = 2), cerebellum (F = 48.83, df = 2), hippocampus (F = 97.80, df = 2) and hypothalamus (F = 27.74, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bax mRNA expression

  increases

  cerebral cortex (F = 57.62, df = 2), cerebellum (F = 48.83, df = 2), hippocampus (F = 97.80, df = 2) and hypothalamus (F = 27.74, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bax mRNA expression

  increases

  cerebral cortex (F = 57.62, df = 2), cerebellum (F = 48.83, df = 2), hippocampus (F = 97.80, df = 2) and hypothalamus (F = 27.74, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bax mRNA expression

  increases

  cerebral cortex (F = 57.62, df = 2), cerebellum (F = 48.83, df = 2), hippocampus (F = 97.80, df = 2) and hypothalamus (F = 27.74, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bax protein expression and activated caspase 3

  increases

  cerebral cortex (F = 23.59, df = 2), cerebellum (F = 5.78, df = 2), and hippocampus (F = 6.14, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bax protein expression and activated caspase 3

  increases

  cerebral cortex (F = 23.59, df = 2), cerebellum (F = 5.78, df = 2), and hippocampus (F = 6.14, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bax protein expression and activated caspase 3

  increases

  cerebral cortex (F = 23.59, df = 2), cerebellum (F = 5.78, df = 2), and hippocampus (F = 6.14, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bcl2 mRNA expression

  decreases

  cerebral cortex (F = 243.29, df = 2), cerebellum (F = 58.96, df = 2), hippocampus (F = 114.14, df = 2) and hypothalamus (F = 222.61, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bcl2 mRNA expression

  decreases

  cerebral cortex (F = 243.29, df = 2), cerebellum (F = 58.96, df = 2), hippocampus (F = 114.14, df = 2) and hypothalamus (F = 222.61, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bcl2 mRNA expression

  decreases

  cerebral cortex (F = 243.29, df = 2), cerebellum (F = 58.96, df = 2), hippocampus (F = 114.14, df = 2) and hypothalamus (F = 222.61, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bcl2 mRNA expression

  decreases

  cerebral cortex (F = 243.29, df = 2), cerebellum (F = 58.96, df = 2), hippocampus (F = 114.14, df = 2) and hypothalamus (F = 222.61, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bcl2 protein expression

  decreases

  cerebral cortex (F = 34.07, df = 2), cerebellum (F = 81.03, df = 2), and hippocampus (F = 60.35, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bcl2 protein expression

  decreases

  cerebral cortex (F = 34.07, df = 2), cerebellum (F = 81.03, df = 2), and hippocampus (F = 60.35, df = 2)

  PMID:25009784 · one of two readings recorded this

• Bcl2 protein expression

  decreases

  cerebral cortex (F = 34.07, df = 2), cerebellum (F = 81.03, df = 2), and hippocampus (F = 60.35, df = 2)

  PMID:25009784 · one of two readings recorded this

• brain reduced glutathione by region

  decreases, decreased in all brain regions studied versus control and MTX control

  Not recorded as a finding: reduced-glutathione node is erythrocyte, whole blood or plasma; this is brain tissue

  The activity of reduced glutathione was decreased in the entire brain regions studied such as cerebral cortex (F = 62, df = 2), cerebellum (F = 39, df = 2), midbrain (F = 40, df = 2), pons-medulla (F = 38, df = 2), hippocampus (F = 33, df = 2) and hypothalamus (F = 50, df = 2) in aspartame treated MTX animals when compared to control and MTX treated control.

  PMID:25009784 · one of two readings recorded this

• brain-region superoxide dismutase, catalase, glutathione peroxidase and reduced glutathione in tissue homogenate

  increases, SOD activity increased significantly in aspartame-treated MTX animals in all six brain regions versus control and MTX control

  Not recorded as a finding: Outcome nodes superoxide-dismutase-activity, catalase-activity, glutathione-peroxidase-activity and reduced-glutathione are defined on erythrocyte lysate, whole blood, plasma or serum; these are brain-region homogenates, so they are near misses and are recorded in the mechanism lane instead

  Activity of SOD increased significantly in aspartame treated MTX animals in the regions cerebral cortex (F = 8.7, df = 2), cerebellum (F = 8.9, df = 2), midbrain (F = 25, df = 2), pons-medulla (F = 21, df = 2), hippocampus (F = 119, df = 2) and hypothalamus (F = 11, df = 2) when compared to control and MTX treated control.

  PMID:25009784 · one of two readings recorded this

• glutathione reductase activity

  decreases

  cerebral cortex (F = 4.11, df = 2), cerebellum (F = 6.67, df = 2), midbrain (F = 8.42, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 172, df = 2) and hypothalamus (F = 20, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione reductase activity

  decreases

  cerebral cortex (F = 4.11, df = 2), cerebellum (F = 6.67, df = 2), midbrain (F = 8.42, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 172, df = 2) and hypothalamus (F = 20, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione reductase activity

  decreases

  cerebral cortex (F = 4.11, df = 2), cerebellum (F = 6.67, df = 2), midbrain (F = 8.42, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 172, df = 2) and hypothalamus (F = 20, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione reductase activity

  decreases

  cerebral cortex (F = 4.11, df = 2), cerebellum (F = 6.67, df = 2), midbrain (F = 8.42, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 172, df = 2) and hypothalamus (F = 20, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione reductase activity

  decreases

  cerebral cortex (F = 4.11, df = 2), cerebellum (F = 6.67, df = 2), midbrain (F = 8.42, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 172, df = 2) and hypothalamus (F = 20, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione reductase activity

  decreases

  cerebral cortex (F = 4.11, df = 2), cerebellum (F = 6.67, df = 2), midbrain (F = 8.42, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 172, df = 2) and hypothalamus (F = 20, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione-S-transferase activity

  increases

  cerebral cortex (F = 71, df = 2), cerebellum (F = 33, df = 2), midbrain (F = 87, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 32, df = 2) and hypothalamus (F = 72, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione-S-transferase activity

  increases

  cerebral cortex (F = 71, df = 2), cerebellum (F = 33, df = 2), midbrain (F = 87, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 32, df = 2) and hypothalamus (F = 72, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione-S-transferase activity

  increases

  cerebral cortex (F = 71, df = 2), cerebellum (F = 33, df = 2), midbrain (F = 87, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 32, df = 2) and hypothalamus (F = 72, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione-S-transferase activity

  increases

  cerebral cortex (F = 71, df = 2), cerebellum (F = 33, df = 2), midbrain (F = 87, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 32, df = 2) and hypothalamus (F = 72, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione-S-transferase activity

  increases

  cerebral cortex (F = 71, df = 2), cerebellum (F = 33, df = 2), midbrain (F = 87, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 32, df = 2) and hypothalamus (F = 72, df = 2)

  PMID:25009784 · one of two readings recorded this

• glutathione-S-transferase activity

  increases

  cerebral cortex (F = 71, df = 2), cerebellum (F = 33, df = 2), midbrain (F = 87, df = 2), pons-medulla (F = 19, df = 2), hippocampus (F = 32, df = 2) and hypothalamus (F = 72, df = 2)

  PMID:25009784 · one of two readings recorded this

• hippocampal neuronal morphology (H&E)

  decreases

  Aspartame + MTX treated animal’s shows the neuronal shrinkage of hippocampal layer due to degeneration of pyramidal cells, as visualized by H&E, when compared to control and MTX controls

  PMID:25009784 · one of two readings recorded this

• lipid peroxidation

  increases

  cerebral cortex (F = 73, df = 2), cerebellum (F = 313, df = 2), midbrain (F = 206, df = 2), pons-medulla (F = 362, df = 2), hippocampus (F = 135, df = 2) and hypothalamus(F = 811, df = 2)

  PMID:25009784 · one of two readings recorded this

• lipid peroxidation

  increases

  cerebral cortex (F = 73, df = 2), cerebellum (F = 313, df = 2), midbrain (F = 206, df = 2), pons-medulla (F = 362, df = 2), hippocampus (F = 135, df = 2) and hypothalamus(F = 811, df = 2)

  PMID:25009784 · one of two readings recorded this

• lipid peroxidation

  increases

  cerebral cortex (F = 73, df = 2), cerebellum (F = 313, df = 2), midbrain (F = 206, df = 2), pons-medulla (F = 362, df = 2), hippocampus (F = 135, df = 2) and hypothalamus(F = 811, df = 2)

  PMID:25009784 · one of two readings recorded this

• lipid peroxidation

  increases

  cerebral cortex (F = 73, df = 2), cerebellum (F = 313, df = 2), midbrain (F = 206, df = 2), pons-medulla (F = 362, df = 2), hippocampus (F = 135, df = 2) and hypothalamus(F = 811, df = 2)

  PMID:25009784 · one of two readings recorded this

• lipid peroxidation

  increases

  cerebral cortex (F = 73, df = 2), cerebellum (F = 313, df = 2), midbrain (F = 206, df = 2), pons-medulla (F = 362, df = 2), hippocampus (F = 135, df = 2) and hypothalamus(F = 811, df = 2)

  PMID:25009784 · one of two readings recorded this

• lipid peroxidation

  increases

  cerebral cortex (F = 73, df = 2), cerebellum (F = 313, df = 2), midbrain (F = 206, df = 2), pons-medulla (F = 362, df = 2), hippocampus (F = 135, df = 2) and hypothalamus(F = 811, df = 2)

  PMID:25009784 · one of two readings recorded this

• plasma methanol level

  increases

  the aspartame treated MTX animals showed a marked increase (F = 140, df = 2) in the plasma methanol level from control and MTX treated control animals

  PMID:25009784 · one of two readings recorded this

• protein carbonyl

  increases

  cerebral cortex (F = 143, df = 2), cerebellum (F = 23, df = 2), midbrain (F = 24, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 64, df = 2) and hypothalamus (F = 132, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein carbonyl

  increases

  cerebral cortex (F = 143, df = 2), cerebellum (F = 23, df = 2), midbrain (F = 24, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 64, df = 2) and hypothalamus (F = 132, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein carbonyl

  increases

  cerebral cortex (F = 143, df = 2), cerebellum (F = 23, df = 2), midbrain (F = 24, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 64, df = 2) and hypothalamus (F = 132, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein carbonyl

  increases

  cerebral cortex (F = 143, df = 2), cerebellum (F = 23, df = 2), midbrain (F = 24, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 64, df = 2) and hypothalamus (F = 132, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein carbonyl

  increases

  cerebral cortex (F = 143, df = 2), cerebellum (F = 23, df = 2), midbrain (F = 24, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 64, df = 2) and hypothalamus (F = 132, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein carbonyl

  increases

  cerebral cortex (F = 143, df = 2), cerebellum (F = 23, df = 2), midbrain (F = 24, df = 2), pons-medulla (F = 14, df = 2), hippocampus (F = 64, df = 2) and hypothalamus (F = 132, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein thiol (sulfhydryl) content

  decreases

  cerebral cortex (F = 78, df = 2), cerebellum (F = 129, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 275, df = 2), hippocampus (F = 17, df = 2) and hypothalamus (F = 239, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein thiol (sulfhydryl) content

  decreases

  cerebral cortex (F = 78, df = 2), cerebellum (F = 129, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 275, df = 2), hippocampus (F = 17, df = 2) and hypothalamus (F = 239, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein thiol (sulfhydryl) content

  decreases

  cerebral cortex (F = 78, df = 2), cerebellum (F = 129, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 275, df = 2), hippocampus (F = 17, df = 2) and hypothalamus (F = 239, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein thiol (sulfhydryl) content

  decreases

  cerebral cortex (F = 78, df = 2), cerebellum (F = 129, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 275, df = 2), hippocampus (F = 17, df = 2) and hypothalamus (F = 239, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein thiol (sulfhydryl) content

  decreases

  cerebral cortex (F = 78, df = 2), cerebellum (F = 129, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 275, df = 2), hippocampus (F = 17, df = 2) and hypothalamus (F = 239, df = 2)

  PMID:25009784 · one of two readings recorded this

• protein thiol (sulfhydryl) content

  decreases

  cerebral cortex (F = 78, df = 2), cerebellum (F = 129, df = 2), midbrain (F = 53, df = 2), pons-medulla (F = 275, df = 2), hippocampus (F = 17, df = 2) and hypothalamus (F = 239, df = 2)

  PMID:25009784 · one of two readings recorded this

• superoxide dismutase (SOD) activity

  increases

  cerebral cortex (F = 8.7, df = 2), cerebellum (F = 8.9, df = 2), midbrain (F = 25, df = 2), pons-medulla (F = 21, df = 2), hippocampus (F = 119, df = 2) and hypothalamus (F = 11, df = 2)

  PMID:25009784 · one of two readings recorded this

• superoxide dismutase (SOD) activity

  increases

  cerebral cortex (F = 8.7, df = 2), cerebellum (F = 8.9, df = 2), midbrain (F = 25, df = 2), pons-medulla (F = 21, df = 2), hippocampus (F = 119, df = 2) and hypothalamus (F = 11, df = 2)

  PMID:25009784 · one of two readings recorded this

• superoxide dismutase (SOD) activity

  increases

  cerebral cortex (F = 8.7, df = 2), cerebellum (F = 8.9, df = 2), midbrain (F = 25, df = 2), pons-medulla (F = 21, df = 2), hippocampus (F = 119, df = 2) and hypothalamus (F = 11, df = 2)

  PMID:25009784 · one of two readings recorded this

• superoxide dismutase (SOD) activity

  increases

  cerebral cortex (F = 8.7, df = 2), cerebellum (F = 8.9, df = 2), midbrain (F = 25, df = 2), pons-medulla (F = 21, df = 2), hippocampus (F = 119, df = 2) and hypothalamus (F = 11, df = 2)

  PMID:25009784 · one of two readings recorded this

• superoxide dismutase (SOD) activity

  increases

  cerebral cortex (F = 8.7, df = 2), cerebellum (F = 8.9, df = 2), midbrain (F = 25, df = 2), pons-medulla (F = 21, df = 2), hippocampus (F = 119, df = 2) and hypothalamus (F = 11, df = 2)

  PMID:25009784 · one of two readings recorded this

• superoxide dismutase (SOD) activity

  increases

  cerebral cortex (F = 8.7, df = 2), cerebellum (F = 8.9, df = 2), midbrain (F = 25, df = 2), pons-medulla (F = 21, df = 2), hippocampus (F = 119, df = 2) and hypothalamus (F = 11, df = 2)

  PMID:25009784 · one of two readings recorded this

• fasting blood glucose

  increases

  Fasting blood glucose (mM) | 5.4±0.2 | 6.9±0.4† | 5.6±0.2 | 7.4±0.6†

  PMID:25313461 · one of two readings recorded this

• Bacteroides/Prevotella spp. (log scale, fecal qPCR)

  no effect, p = 0.244

  Bacteroides/Prevotella spp. | 7.47±0.092 | 7.25±0.142 | 6.46±0.076* | 6.62±0.069* | <0.001 | 0.244 | 0.153

  PMID:25313461 · one of two readings recorded this

• Bifidobacterium spp. (log scale, fecal qPCR)

  no effect, p = 0.062

  Bifidobacterium spp. | 5.51±0.199 | 4.55±0.114 | 6.57±0.313* | 5.97±0.316† | 0.011 | 0.062 | 0.126

  PMID:25313461 · one of two readings recorded this

• blood glucose AUC in OGTT, main effect of APM

  no effect, p = 0.05

  No main effect of APM on blood glucose AUC was observed (p>0.05)

  PMID:25313461 · one of two readings recorded this

• blood glucose AUC in OGTT, main effect of diet

  increases, p = 0.05

  There was a significant main effect of diet for blood glucose AUC wherein HF was higher than CH (p<0.05)

  PMID:25313461 · one of two readings recorded this

The whole record — 639 rows